ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

LEGN Legend Biotech Corporation

42.07
-1.06 (-2.46%)
29 Nov 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Legend Biotech Corporation NASDAQ:LEGN NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -1.06 -2.46% 42.07 41.55 42.99 43.53 42.07 43.255 452,813 22:00:00

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07/11/2024 12:30pm

GlobeNewswire Inc.


Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart


From Nov 2024 to Nov 2024

Click Here for more Legend Biotech Charts.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.

During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.

Investors and other interested parties may join the live webcast through this weblink or by visiting Legend Biotech’s website under Events and Presentation.

About Legend BiotechLegend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR CONTACT:Jessie YeungTel: (732) 956-8271jessie.yeung@legendbiotech.com

PRESS CONTACT:Mary Ann OndishTel: (914) 552-4625media@legendbiotech.com

1 Year Legend Biotech Chart

1 Year Legend Biotech Chart

1 Month Legend Biotech Chart

1 Month Legend Biotech Chart